CG
ATHE

Cutler Group’s Alterity Therapeutics ATHE Stock Holding History

Cutler Group’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3
Closed – – 4000
2018
Q4 		$0 Hold
3
– – ﹤0.01% 3901
2018
Q3 		$0 Hold
3
– – ﹤0.01% 4066
2018
Q2 		$0 Hold
3
– – ﹤0.01% 4161
2018
Q1 		$0 Hold
3
– – ﹤0.01% 4415
2017
Q4 		$0 Hold
3
– – ﹤0.01% 4861
2017
Q3 		$0 Hold
3
– – ﹤0.01% 5817
2017
Q2 		$0 Hold
3
– – ﹤0.01% 6317
2017
Q1 		$0 Hold
3
– – ﹤0.01% 6336
2016
Q4 		$0 Hold
3
– – ﹤0.01% 6463
2016
Q3 		$0 Hold
3
– – ﹤0.01% 6612
2016
Q2 		$0 Hold
3
– – ﹤0.01% 6606
2016
Q1 		$0 Hold
3
– – ﹤0.01% 6444
2015
Q4 		$0 Buy
+3
New +$153 ﹤0.01% 6329

Other funds holding ATHE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return
NFH
NEXT Financial Holdings Houston, Texas $395M AUM
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Cutler Group's ATHE Position: Q1 2019 in Review

Cutler Group sold out of Alterity Therapeutics (ATHE) in Q1 2019, closing a stake of 3 shares.

Cutler Group first reported a position in ATHE in Q4 2015 and held it in 13 quarters. The position peaked at $0 in Q4 2018. 8 funds tracked by Wall St. Rank hold ATHE as of Q1 2019.

  • Cutler Group reported no remaining Alterity Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Cutler Group sold 3 Alterity Therapeutics shares in Q1 2019.
  • Cutler Group first reported a position in Alterity Therapeutics in Q4 2015 and held it in 13 quarters.
  • Cutler Group's Alterity Therapeutics position peaked at $0 in Q4 2018.
  • 8 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q1 2019.

Based on Cutler Group's 13F filing for Q1 2019, filed 10 May 2019.